NEW YORK (GenomeWeb News) – Provista Life Sciences said today that International Health Technology will offer its early-stage breast cancer detection test in the United Kingdom and in Ireland.
 
Under the license agreement, IHT will offer the blood-based Biomarker Translation Test in its BreastHealth UK clinic this summer. The company said it plans to expand the availability of the test to other European Union countries sometime later, but did not provide further details on its timeline.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.